The bone anabolic carotenoid p-hydroxycinnamic acid promotes osteoblast mineralization and suppresses osteoclast differentiation by antagonizing NF-κB activation

International Journal of Molecular Medicine

Volumn 30, Issue 3, 2012, Pages 708-712

  Yamaguchi, Masayoshi ^a   Weitzmann, M Neale ^a,b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c 1305 WMRB ^*  (United States)

Author keywords

Nuclear factor B; Osteoblast; Osteoclast; Osteoporosis; p hydroxycinnamic acid

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARA COUMARIC ACID; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOSYNTHESIS; BONE DEVELOPMENT; BONE MINERALIZATION; CATABOLISM; CONTROLLED STUDY; IN VITRO STUDY; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; COUMARIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; MICE; NF-KAPPA B; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; SMAD PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865195506     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1043     Document Type: Article

References (31)

1. Shea MK and Booth SL: Update on the role of vitamin K in skeletal health. Nutr Rev 66: 549-557, 2008.
2. Yamaguchi M and Weitzmann MN: Quercetin, a potent suppressor of NF-κB and Smad activation in osteoblasts. Int J Mol Med 28: 521-525, 2011.
3. Yamaguchi M and Weitzmann MN: Zinc stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-kappaB activation. Mol Cell Biochem 355: 179-186, 2011.
4. 2 stimulates osteoblastogenesis and suppresses osteoclastogenesis by suppressing NF-κB activation. Int J Mol Med 27: 3-14, 2011.
5. Yamaguchi M, Arbiser JL and Weitzmann MN: Honokiol stimulates osteoblastogenesis by suppressing NF-κB activation. Int J Mol Med 28: 1049-1053, 2011.
6. Yamaguchi M and Weitzmann MN: The bone anabolic carotenoids p-hydroxycinnamic acid and β-cryptoxanthin antagonize NF-κB activation in MC3T3 preosteoblasts. Mol Med Rep 2: 641-644, 2009.
7. Yamaguchi M and Weitzmann MN: The bone anabolic carotenoid β-cryptoxanthin enhances transforming growth factor-β1-induced Smad activation in MC3T3 preosteoblasts. Int J Mol Med 24: 671-675, 2009.
8. Vaira S, Alhawagri M, Anwisye I, Kitaura H, Faccio R and Novack DV: RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest 118: 2088-2097, 2008. (Pubitemid 351872328)
9. Boyce BF, Xing L, Franzoso G and Siebenlist U: Required and nonessential functions of nuclear factor-kappaB in bone cells. Bone 25: 137-139, 1999. (Pubitemid 29322078)
10. Strait K, Li Y, Dillehay DL and Weitzmann MN: Suppression of NF-κB activation blocks osteoclastic bone resorption during estrogen deficiency. Int J Mol Med 21: 521-525, 2008. (Pubitemid 351802648)
11. Dai S, Hirayama T, Abbas S and Abu-Amer Y: The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 279: 37219-37222, 2004. (Pubitemid 39195425)
12. Feng R, Anderson G, Xiao G, et al: SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood 109: 2130-2138, 2007. (Pubitemid 46348215)
13. Nanes MS: Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 321: 1-15, 2003.
14. Li Y, Li A, Strait K, Zhang H, Nanes MS and Weitzmann MN: Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation, through NF-kappaB. J Bone Miner Res 22: 646-655, 2007. (Pubitemid 351339092)
15. Wahl EC, Aronson J, Liu L, et al: Restoration of regenerative osteoblastogenesis in aged mice: modulation of TNF. J Bone Miner Res 25: 114-123, 2010.
16. Wahl EC, Aronson J, Liu L, et al: Direct bone formation during distraction osteogenesis does not require TNFalpha receptors and elevated serum TNFalpha fails to inhibit bone formation in TNFR1 deficient mice. Bone 46: 410-417, 2010.
17. Chang J, Wang Z, Tang E, et al: Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med 15: 682-689, 2009.
18. Yamazaki M, Fukushima H, Shin M, et al: Tumor necrosis factor alpha represses bone morphogenetic protein (BMP) signaling by interfering with the DNA binding of Smads through the activation of NF-kappaB. J Biol Chem 284: 35987-35995, 2009.
19. Guo R, Yamashita M, Zhang Q, et al: Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins. J Biol Chem 283: 23084-23092, 2008.
20. Eliseev RA, Schwarz EM, Zuscik MJ, O'Keefe RJ, Drissi H and Rosier RN: Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NFkappaB. Exp Cell Res 312: 40-50, 2006. (Pubitemid 41668590)
21. Lai YL and Yamaguchi M: Phytocomponent p-hydroxycinnamic acid stimulates bone formation and inhibits bone resorption in rat femoral tissues in vitro. Mol Cell Biochem 292: 45-52, 2006. (Pubitemid 44697398)
22. Lai YL and Yamaguchi M: Phytocomponent p-hydroxycinnamic acid inhibits osteoclast-like cell formation in mouse bone marrow cultures. Int J Mol Med 19: 123-128, 2007.
23. Yamaguchi M, Lai YL, Uchiyama S and Nakagawa T: Oral administration of phytocomponent p-hydroxycinnamic acid prevents bone loss in ovariectomized rats. Mol Cell Biochem 311: 31-36, 2008.
24. Yamaguchi M, Uchiyama S and Lai YL: Oral administration of phytocomponent p-hydroxycinnamic acid has a preventive effect on bone loss in streptozotocin-induced diabetic rats. Int J Mol Med 19: 803-807, 2007.
25. Sugimoto E and Yamaguchi M: Anabolic effect of genistein in osteoblastic MC3T3-E1 cells. Int J Mol Med 5: 515-520, 2000.
26. Abramoff MD, Magelhaes PJ and Ram SJ: Image processing with ImageJ. Biophotonics Int 11: 36-42, 2004.
27. Weitzmann MN and Pacifici R: Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116: 1186-1194, 2006.
28. Cenci S, Weitzmann MN, Roggia C, et al: Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 106: 1229-1237, 2000.
29. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP and Teitelbaum SL: TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106: 1481-1488, 2000. (Pubitemid 32038586)
30. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A and Abu-Amer Y: Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276: 563-568, 2001. (Pubitemid 32050352)
31. Fuller K, Murphy C, Kirstein B, Fox SW and Chambers TJ: TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 143: 1108-1118, 2002. (Pubitemid 34164059)